- Home
- LUCD
as 11-25-2024 3:37pm EST
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 38.4M | IPO Year: | 2021 |
| Target Price: | $3.69 | AVG Volume (30 days): | 535.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $1.58 | Next Earning Date: | 11-13-2024 |
| Revenue: | $4,189,000 | Revenue Growth: | 179.27% |
| Revenue Growth (this year): | 88.47% | Revenue Growth (next year): | 238.94% |
Latest Lucid Diagnostics Inc. News
LUCD Breaking Stock News: Dive into LUCD Ticker-Specific Updates for Smart Investing
PR Newswire
5 days ago
Lucid Diagnostics Submits Clinical Evidence Package to MolDX Seeking Medicare Coverage for EsoGuard® Esophageal DNA Test
PR Newswire
7 days ago
Lucid Diagnostics to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Thomson Reuters StreetEvents
10 days ago
Q3 2024 PAVmed Inc Earnings Call
GuruFocus.com
11 days ago
PAVmed Inc (PAVM) Q3 2024 Earnings Call Highlights: Record Revenue and Strategic Restructuring
PR Newswire
11 days ago
PAVmed Provides Business Update and Third Quarter 2024 Financial Results
GuruFocus.com
12 days ago
Lucid Diagnostics Inc (LUCD) Q3 2024 Earnings Call Highlights: Record Revenue Growth Amid ...
PR Newswire
12 days ago
Lucid Diagnostics Provides Business Update and Third Quarter 2024 Financial Results
PR Newswire
18 days ago
Lucid Diagnostics' ESOGUARD BE-1 Prospective Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing Accepted for Peer-Reviewed Publication
Compare LUCD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LUCD Lucid Diagnostics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.